PFE vs. BMY, ZTS, ABBV, MRK, JNJ, ABT, SNY, VRTX, NVS, and REGN
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Bristol-Myers Squibb (BMY), Zoetis (ZTS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Novartis (NVS), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "pharmaceutical preparations" industry.
Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.
In the previous week, Pfizer had 9 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 41 mentions for Pfizer and 32 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 0.70 beat Pfizer's score of 0.42 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
Pfizer received 411 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pfizer currently has a consensus target price of $35.86, suggesting a potential upside of 25.20%. Bristol-Myers Squibb has a consensus target price of $60.00, suggesting a potential upside of 36.27%. Given Bristol-Myers Squibb's higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Pfizer.
Pfizer has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Pfizer has a net margin of -0.56% compared to Bristol-Myers Squibb's net margin of -13.50%. Bristol-Myers Squibb's return on equity of 8.83% beat Pfizer's return on equity.
Bristol-Myers Squibb has lower revenue, but higher earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.
Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.5%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Pfizer beats Bristol-Myers Squibb on 13 of the 20 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
